Zacks Research Predicts Q4 2024 Earnings for Shockwave Medical,
December 3, 2023
🌥️Trending News
Shockwave Medical ($NASDAQ:SWAV), Inc., a medical device company, has become the center of attention as Zacks Research has released their prediction of the company’s earnings for the fourth quarter of 2024. Shockwave Medical, Inc. is a leader in the development of innovative solutions to improve cardiovascular health. Their products utilize high-energy shock waves to treat peripheral artery disease, and its dedicated team of engineers and clinicians have worked hard to revolutionize the way physicians use medical technology in treating vascular diseases. The company has seen a strong growth in its share price over the past year, and analysts are now expecting fourth quarter earnings to be higher than they were in the prior year. The financial analysts cite a strong product pipeline and expanding market share as the reasons for their optimism.
These impressive earnings predictions could mean great news for investors in Shockwave Medical, Inc.’s stock. If these estimates are correct, then the company’s fourth quarter financial results could be much improved over the previous year’s performance, potentially leading to a substantial increase in the value of its shares. If these estimates prove to be accurate, then investors may be looking at a very rosy future for Shockwave Medical’s stock.
Earnings
According to their latest earning report as of September 30 2021 for FY2023 Q3, Shockwave Medical earned 65.16M USD in total revenue and 1.95M USD in net income, a 50.4% decrease in total revenue and 94.4% decrease in net income compared to the previous year. Despite the decrease in their most recent report, Shockwave Medical’s total revenue has seen an impressive increase over the past three years, from 65.16M USD to 186.02M USD. It remains to be seen whether or not Shockwave Medical will meet the predictions for the fourth quarter of 2024.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Shockwave Medical. More…
| Total Revenues | Net Income | Net Margin |
| 671.28 | 243.88 | 36.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Shockwave Medical. More…
| Operations | Investing | Financing |
| 176.79 | -418.74 | 610.16 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Shockwave Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.47k | 872.71 | 16.3 |
Key Ratios Snapshot
Some of the financial key ratios for Shockwave Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 124.4% | – | 25.1% |
| FCF Margin | ROE | ROA |
| 21.3% | 17.3% | 7.1% |
Stock Price
Monday saw Shockwave Medical, Inc. (SHOCKWAVE MEDICAL) stock open at $173.6 and close at $170.4, a drop of 2.8% from its previous closing price of 175.3. This recently follows Zacks Investment Research’s prediction of SHOCKWAVE MEDICAL reported earnings for the fourth quarter of 2024. According to Zacks, the company is likely to see an increase in earnings, meaning that shareholders may be able to reap the rewards of this boost in revenue. This positive outlook is supported by the company’s recent investments and expansions into new markets, as well as the continued focus on innovative medical technology solutions. Live Quote…
Analysis
At GoodWhale, we analyzed SHOCKWAVE MEDICAL‘s financials to get an insight on their health. Our Star Chart showed that the company has an intermediate health score of 6/10 with regard to its cashflows and debt. This implies that the company might be able to sustain future operations in times of crisis. From our analysis, SHOCKWAVE MEDICAL is classified as a ‘gorilla’, meaning they have achieved stable and high revenue or earning growth due to their competitive advantage in their industry. This type of company would be attractive to growth investors, as they are looking for companies that can grow quickly and sustainably. Additionally, SHOCKWAVE MEDICAL is strong in assets, growth, and profitability in terms of financials. They are weak in dividend, which makes them less attractive to income investors. Therefore, we believe that growth investors would be most interested in SHOCKWAVE MEDICAL due to their competitive advantages and potential for high growth. More…
Peers
The medical device industry is an ever-evolving landscape, with many companies competing to develop the most impactful and innovative solutions. One of the major players in this field is ShockWave Medical Inc, which has recently been engaged in a fierce competition with other notable players such as Inspire Medical Systems Inc, Inari Medical Inc, and INVO Bioscience Inc. Each of these companies has their own unique approach to developing cutting-edge medical technology, and their competition is driving innovation and progress in the industry.
– Inspire Medical Systems Inc ($NYSE:INSP)
Inspire Medical Systems Inc is a medical device company that specializes in the development of minimally invasive solutions for treating obstructive sleep apnea (OSA). The company has a market capitalization of 6.71 billion US dollars as of 2022, making it one of the larger companies in its sector. The company’s Return on Equity (ROE) is -8.55%, which suggests that the company is not generating a positive return on its shareholders’ investments. This is likely due to the high costs associated with R&D and clinical trials associated with developing new products and treatments. Despite this, Inspire Medical Systems Inc remains a leader in its sector, having developed innovative solutions that are helping to improve the lives of patients around the world.
– Inari Medical Inc ($NASDAQ:NARI)
Inari Medical Inc is a medical technology company that develops innovative medical devices for treating vascular diseases. The company has a market cap of 3.67 billion USD as of 2022, indicating a strong market presence and demonstrating that investors are confident in the company’s long-term prospects. Additionally, Inari Medical Inc has a return on equity of -2.93%, which suggests that the company has not been able to generate profits from its investments. This could be due to the company’s investments into research and development, as well as its expensive start-up costs.
– INVO Bioscience Inc ($NASDAQ:INVO)
INVO Bioscience Inc is a medical device company that focuses on developing and commercializing innovative products for the treatment of infertility. The company has a market cap of 7.3M as of 2022, indicating that its current market value is relatively small compared to its competitors. Its Return on Equity of -210.86% shows that the company is not performing well, as it has been burning through cash and not generating sufficient returns on its investments.
Summary
Shockwave Medical Inc. (SWAV) is a medical device company that is revolutionizing the treatment of coronary and peripheral artery disease, as well as kidney and heart failure. The analysts also noted that Shockwave Medical has outperformed its peers in terms of growth, profitability, and market capitalization. Despite the potential for further growth, investors should be aware that Shockwave Medical is relatively new, so there is a risk associated with any investment in the company. However, long-term investors may be rewarded with significant returns if the company can maintain its current momentum.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
